Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer

被引：3

作者：

Hamada, Akinobu ^{[1
,2
]}

Sasaki, Ji-ichiro ^{[1
]}

Saeki, Sho ^{[2
]}

Iwamoto, Norihiro ^{[3
]}

Inaba, Megumi ^{[8
]}

Ushijima, Sunao ^{[8
]}

Urata, Maki ^{[4
]}

Kishi, Hiroto ^{[4
]}

Fujii, Shinji ^{[5
]}

Semba, Hiroshi ^{[5
]}

Kashiwabara, Kosuke ^{[6
]}

Tsubata, Yukari ^{[7
]}

Kai, Yuki ^{[2
]}

Isobe, Takeshi ^{[7
]}

Kohrogi, Hirotsugu ^{[2
]}

Saito, Hideyuki ^{[1
,2
]}

机构：

[1] Kumamoto Univ Hosp, Kumamoto, Japan

[2] Kumamoto Univ, Kumamoto, Japan

[3] Saiseikai Kumamoto Hosp, Kumamoto, Japan

[4] Kumamoto City Hosp, Kumamoto, Japan

[5] Kumamoto Reg Med Ctr, Kumamoto, Japan

[6] Kumamoto Med Ctr, Kumamoto, Japan

[7] Shimane Univ Hosp, Matsue, Shimane, Japan

[8] Kumamoto City Hosp, Kumamoto, Japan

来源：

PHARMACOGENOMICS | 2012年 / 13卷 / 05期

关键词：

ABCB1; erlotinib; Japanese; P-glycoprotein; pharmacokinetic; polymorphism; toxicity; TYROSINE KINASE INHIBITOR; P-GLYCOPROTEIN; GENETIC POLYMORPHISMS; MULTIDRUG-RESISTANCE; FUNCTIONAL POLYMORPHISMS; ANTIEPILEPTIC DRUGS; CLINICAL-RELEVANCE; TRANSPORTER ABCB1; SOLID TUMORS; IN-VIVO;

D O I：

10.2217/PGS.11.176

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aims: We analyzed the association of ABCB1 polymorphisms with erlotinib-induced toxicity and the pharmacokinetics in patients with non-small-cell lung cancer. Materials & methods: After erlotinib 150 mg was administered to 50 patients, ABCB1 polymorphisms were analyzed via either TaqMan (R) assays or direct nucleotide sequencing. Plasma concentrations were measured by HPLC. Results: The trough concentration at steady state in patients with the ABCB1 1236TT-2677TT-3435TT genotype was higher compared with others groups (p = 0.021) and patients carrying this genotype had a higher risk of developing higher grade 2 toxicity (p = 0.012). Conclusion: The present study suggested that the ABCB1 1236TT-2677TT-3435T1 genotype was associated with higher plasma concentration and the risk of developing higher toxicity in patients treated with erlotinib.

引用

页码：615 / 624

页数：10

共 50 条

[1] Effect of genetic polymorphisms on erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer
Endo-Tsukude, Chihiro
Sasaki, Ji-ichiro
Saeki, Sho
Iwamoto, Norihiro
Inaba, Megumi
Ushijima, Sunao
Kishi, Hiroto
Fujii, Shinji
Semba, Hiroshi
Kashiwabara, Kosuke
Tsubata, Yukari
Kai, Yuki
Saito, Hideyuki
Isobe, Takeshi
Kohrogi, Hirotsugu
Hamada, Akinobu
CANCER RESEARCH, 2015, 75
[2] Effect of genetic polymorphisms on erlotinib pharmacokinetics and toxicity in patients with non-small-cell lung cancer
Kishi, Hiroto
Endo, Chihiro
Sasaki, Ji-ichiro
Saeki, Sho
Iwamoto, Norihiro
Inaba, Megumi
Isobe, Takeshi
Kourogi, Hirotsugu
Saito, Hideyuki
Hamada, Akinobu
ANNALS OF ONCOLOGY, 2015, 26 : 84 - 84
[3] Association of ABCB1 polymorphism and erlotinib toxicity with efficacy in patients with non-small cell lung cancer (NSCLC)
Saeki, S.
Sasaki, J.
Hamada, A.
Iwamoto, N.
Inaba, M.
Kishi, H.
Fujii, S.
Ushijima, S.
Semba, H.
Kohrogi, H.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[4] EFFECT OF GENETIC POLYMORPHISMS ON ERLOTINIB PHARMACOKINETICS AND ADVERSE EVENTS JAPANESE PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC).
Hamada, A.
Sasaki, J.
Saeki, S.
Inaba, M.
Ushijima, S.
Kishi, H.
Fujii, S.
Semba, H.
Kashiwabara, K.
Tsubata, Y.
Tsukude, C. E.
Shimizu, Y. K.
Isobe, T.
Kohrog, H.
Saito, H.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S25 - S25
[5] Effect of genetic polymorphisms on erlotinib pharmacokinetics and toxicity in Japanese patients with non-small cell lung cancer.
Saeki, Sho
Sasaki, Jiichiro
Iwamoto, Norihiro
Inaba, Megumi
Ushijima, Sunao
Kishi, Hiroto
Fujii, Shinji
Semba, Hiroshi
Kashiwabara, Kosuke
Sakata, Shinya
Kai, Yuki
Tsubata, Yukari
Isobe, Takeshi
Endo-Tsukude, Chihiro
Kohrogi, Hirotsugu
Saito, Hideyuki
Hamada, Akinobu
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[6] Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters
Endo-Tsukude, Chihiro
Sasaki, Ji-ichiro
Saeki, Sho
Iwamoto, Norihiro
Inaba, Megumi
Ushijima, Sunao
Kishi, Hiroto
Fujii, Shinji
Semba, Hiroshi
Kashiwabara, Kosuke
Tsubata, Yukari
Hayashi, Mitsuhiro
Kai, Yuki
Saito, Hideyuki
Isobe, Takeshi
Kohrogi, Hirotsugu
Hamada, Akinobu
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2018, 41 (01) : 47 - 56
[7] Erlotinib in non-small-cell lung cancer
Gridelli, Cesare
Rossi, Antonio
Malone, Paolo
Colantuoni, Giuseppe
Del Gaizo, Filomena
Ferrara, Carmine
Nicolella, Dario
Guerriero, Ciro
EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2579 - 2592
[8] Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer
Emoto-Yamamoto, Y.
Iida, S.
Kawanishi, T.
Fukuoka, M.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (02) : 232 - 239
[9] Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma
Takahiro Kobayashi
Masatomo Miura
Maiko Abumiya
Yumiko Akamine
Fumiko Ito
Naoto Takahashi
Medical Oncology, 2019, 36
[10] Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma
Kobayashi, Takahiro
Miura, Masatomo
Abumiya, Maiko
Akamine, Yumiko
Ito, Fumiko
Takahashi, Naoto
MEDICAL ONCOLOGY, 2019, 36 (06)

← 1 2 3 4 5 →